In what ways does keytruda change cancer prognosis?

Keytruda shifts survival curves for several advanced cancers by extending median overall survival and progression-free survival compared with chemotherapy or placebo.

How does Keytruda improve outcomes in metastatic melanoma?
In untreated patients, median overall survival reached 38 months with Keytruda versus 16 months with ipilimumab alone. Five-year survival rose from roughly 5 % in the pre-checkpoint era to about 34 % when patients received Keytruda first-line.

What survival gains appear in non-small cell lung cancer?
For PD-L1–high tumors, median overall survival doubled from 14 months on chemotherapy to 30 months on Keytruda monotherapy. In the broader PD-L1–positive population, adding Keytruda to chemotherapy lifted two-year survival from 28 % to 45 %.

Does the drug change prognosis in earlier-stage disease?
Adjuvant use after resection of stage III melanoma cut the risk of recurrence or death by 43 % at three years. In stage IB–IIIA non-small cell lung cancer, one year of Keytruda after surgery and chemotherapy lowered recurrence risk by 27 % at two years.

Which tumor types still show modest or no benefit?
PD-L1–low or microsatellite-stable colorectal cancers rarely respond, leaving prognosis essentially unchanged. In renal-cell carcinoma, Keytruda plus axitinib improves progression-free survival but overall-survival gains remain modest once patients receive subsequent therapies.

What factors most influence individual prognosis on Keytruda?
High tumor mutational burden and PD-L1 expression above 50 % predict deeper, more durable responses. Patients who develop immune-related adverse events often experience longer survival, but severe toxicities can interrupt treatment and reverse early gains.

How long do responses typically last?
Complete responses in melanoma can persist beyond five years off therapy. In lung cancer, roughly 20 % of responders remain progression-free at three years, suggesting a tail on the survival curve that was absent with chemotherapy.

When does patent protection end?
Merck’s composition-of-matter patent for pembrolizumab expires in 2028 in the United States; secondary patents on formulation and dosing may extend market exclusivity into the early 2030s. DrugPatentWatch lists the full patent family and anticipated generic entry dates.